苯乙酸对结直肠癌细胞中C-myc基因表达的影响

目的　观察诱导分化剂苯乙酸 (Phenylacetate,PA)抑制结直肠癌细胞HCT 8增殖过程中C myc基因表达的变化。方法　体外细胞培养 ,运用流式细胞技术观察苯乙酸对HCT 8细胞凋亡的影响。应用原位分子杂交方法观察应用PA后对HCT 8细胞C mycmRNA表达的情况。结果　PA组HCT 8细胞G1期比例从 32 3%增加到 6 1 0 % ,S期比例从 5 9 6 %下降到 2 9 7%。PA治疗后HCT 8细胞C mycmRNA表达阳性表达率为 (12 0 5± 7 92 ) % ,显著低于非治疗组中的阳性率 (5 5 15± 2 1 6 4 ) % ,P <0 0 1。通过细胞周期的检测发现 ,PA抑制大肠癌细胞HCT 8增殖的方式为抑制细胞周期G1期比例。结论　PA通过下调结直肠癌细胞C mycmRNA的生成以及细胞生长G1期阻滞在肿瘤诱导分化治疗方面发挥作用     

视场角设置对虚拟环境中目标判断的影响

目的探讨不同视场角参数对虚拟环境中目标判断的影响规律 ,找出最佳视场角参数。方法利用自行研制基于PC平台的虚拟现实 (VR)实验系统 ,选定 45名年龄在 2 3～ 5 8岁被试者并完成大小与角度判断的实验设计。首先进行 30 0人次的预实验 ,确定引起虚拟环境中目标判断差错的视场角及相应观察任务的差别等级 ,然后开始单因素、4水平的完全随机正式实验。结果方差分析表明 ,不同的虚拟环境视场角对目标判断的真实性有显著性影响 ,当视场角为 60°时 ,目标判断的正确率最大。结论利用VR技术进行载人航天器工效设计、操作训练或其它任务的研究时 ,应考虑视场角的作用 ,适合目标大小判断的视场角参数值宜取 60°,以便获得最大的工效     

胰腺闭合性损伤的外科诊治探讨

目的探讨胰腺闭合性损伤诊断和外科处理的方法。方法分析20例胰腺闭合性损伤的诊断，手术处理和预后。结果17例治愈，死亡3例，死亡率15，并发胰瘘2例，假性囊肿2例，腹腔脓肿1例。结论CT、B超及血淀粉酶检查对胰腺损伤仍具有一定的诊断价值。术中关键是保持警觉，按胰腺损伤情况选择适当的术式。     

来氟米特治疗类风湿关节炎患者的护理

对48例住院期间服用来氟米特(LEF)的类风湿关节炎(RA)患者进行心理护理、不良反应的护理以及出院指导等护理干预.结果48例患者都能够积极配合用药,学会自我保健,无严重的不良反应,关节功能得到改善.提示通过护理干预可使服用LEF的RA患者减轻不良反应,提高生活质量,增强对治疗的信心.     

细胞移植用于心肌修复--细胞心肌成形术的研究进展

由于心肌细胞的增殖能力很低，细胞移植作为一种新的治疗方法用于改善心功能及心肌活力已受到广泛的关注。目前已有胚胎干细胞、骨髓间充质干细胞和内皮干细胞在体外诱导分化为心肌细胞；动物实验中用于心肌移植的细胞有胚胎心肌细胞、造血干细胞、骨髓间充质干细胞、骨骼肌成肌细胞、内皮干细胞、肝干细胞和神经干细胞。其中成肌细胞移植用来改善心肌梗死后的心脏功能，已有临床报道，并取得成功。     

改良W形回肠代膀胱术的疗效观察(附36例报告)

目的 :探讨改良W形回肠代膀胱术的疗效。方法 :对 36例膀胱肿瘤患者行根治性膀胱切除、W形回肠代膀胱术 ,并对术式进行改进。结果 :36例手术时间平均 4 .2h。术后 31例随访 4～ 19个月 ,平均 10 .6个月 ,无严重并发症 ,均无瘤生存。患者一般于术后 3周自主可控性排尿 ,日间尿控率为 10 0 % ,术后 3、6、12个月夜间尿失禁发生率分别为 2 2 .5 %、11.1%及 6 .2 %。术后 6个月尿动力学检查膀胱容量 (36 0± 30 )ml,最大尿流率 (13.6± 2 .6 )ml/s,剩余尿量 (11.5± 5 .8)ml,充盈期膀胱压力明显低于尿道闭合压。新膀胱造影发现新膀胱呈球形 ,完全位于盆腔 ,未见输尿管反流。B超及IVU检查发现原上尿路积水 4例均明显减轻 ,其余未发现输尿管狭窄和上尿路积水征象。无高氯性酸中毒 ,肾功能正常。结论 :改良W形回肠代膀胱术手术时间短 ,操作简单 ,创伤轻 ,并发症少 ;新膀胱容量大 ,内压低 ,顺应性好 ,功能接近于正常膀胱 ,保持原位排尿 ,明显提高了患者术后生活质量 ,值得临床推广应用。     

改良电针痉挛连续两次发作治疗重性抑郁症疗效分析

目的　探讨改良电针痉挛连续两次发作治疗重性抑郁症的疗效。方法　使用YA型电针痉挛治疗仪 ,对 64例重性抑郁症患者进行连续两次发作 (试验组 )和单次发作 (对照组 )治疗 ,采用HAMD抑郁量表评分。结果　试验组临床显效率为 82 3 % ,对照组为 60 0 % ,试验组的疗效显著性地优于对照组 (χ2 =3 94,P <0 0 5 )。HAMD抑郁量表评定 :两组治疗前后总分均值比较均有显著差异 (P <0 0 1) ,试验组和对照组治疗后总分均值有显著差异 (t=5 .10 8,P <0 0 1) ;两组 4次发作治疗后总分均值比较试验组显效快于对照组 ;试验组的绝望感、认知障碍、迟滞因子分均值减低比对照组更明显 (P <0 0 1)。结论　改良电针痉挛连续两次发作疗法见效快、疗效好 ,无明显副作用 ,是治疗重性抑郁症的一种新方法     

Reduced expression of CD69 and adhesion molecules of T lymphocytes in asthmatic children receiving immunotherapy

T lymphocytes play a fundamental role in the initiation and regulation of chronic inflammatory responses in patients with asthma. CD69 is an early marker of T‐cell activation. The levels of intercellular adhesion molecule‐1 (ICAM‐1, CD54) and L ‐selectin have been reported to increase in patients with allergic diseases and asthma. The present study was therefore undertaken to investigate the expression of CD69, CD54, and L ‐selectin by T lymphocytes of children with asthma, before and after immunotherapy. Eighteen children newly diagnosed with asthma, 11 good and nine poor responders to immunotherapy, and 16 normal subjects, were enrolled in this study. The percentages of CD69⁺, CD54⁺, and CD62L⁺ cells in T lymphocytes were measured by using flow cytometry. The levels of CD69, CD54, and CD62L in serum and culture supernatants were determined by using enzyme‐linked immunosorbent assay (ELISA). The expression of CD69 and CD54 on CD3⁺ T lymphocytes was significantly higher in children with asthma than in control patients. All the patient groups expressed (spontaneously and following stimulation with phorbol myristate acetate and ionomycin together with mite‐extract proteins) greater amounts of CD69 and CD54 than did control subjects. With long‐term immunotherapy, the percentages of CD69⁺ and CD54⁺ T lymphocytes were significantly lower in patients with a good response to immunotherapy. Our results also showed significantly lower serum L ‐selectin levels following immunotherapy. In conclusion, successful immunotherapy resulted in decreased expression and production of CD69 and CD54. These results may explain, in part, the clinical efficacy of immunotherapy.     

Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas.

Epidermal growth factor receptor plays an important role in the pathogenesis of many malignancies. Various growth factors, including epidermal growth factor receptor, have been shown to influence pituitary tumor growth and differentiation. To analyze the role of epidermal growth factor receptor in pituitary tumor development, we examined normal pituitaries (n=8), pituitary adenomas (n=158), and pituitary carcinomas (n=7) for expression of epidermal growth factor receptor protein and messenger RNA using tissue microarrays and RT-PCR. We also examined (a) the expression of phospho-epidermal growth factor receptor, the activated form of epidermal growth factor receptor, in pituitary tumors and normal pituitaries by immunohistochemistry and (b) the effects on epidermal growth factor receptor expression of treating pituitary cells (HP75 cell line) with epidermal growth factor. Epidermal growth factor receptor and the phosphorylated variant expression were present in normal pituitary cells. Epidermal growth factor receptor messenger RNA was also detected in normal pituitaries, pituitary adenomas, and carcinomas by in situ hybridization and RT-PCR. Most pituitary adenomas showed expression of epidermal growth factor receptor and the phosphorylated variant. Nonfunctional adenomas showed higher levels of expression of epidermal growth factor receptor (76 vs 34%) and of phospho-epidermal growth factor receptor (26 vs 8%) as compared to functional adenomas. Five of seven pituitary carcinomas showed strong expression of both epidermal growth factor receptor and phospho-epidermal growth factor receptor. When a human pituitary cell line (HP75) was cultured in the presence of epidermal growth factor receptor, there was an increase in the levels of both epidermal growth factor receptor and phospho-epidermal growth factor receptor after 5 h of treatment, thus confirming that epidermal growth factor receptor signaling was active in pituitary tumors. These results indicate that activated epidermal growth factor receptor is expressed in pituitary adenomas and carcinomas. Higher levels in pituitary carcinomas suggest a role in pituitary tumor progression.